INTRODUCTION
International Prognostic Score System (DIPSS) 6 and the DIPSS-Plus 7 . At this time, a therapeutic agent which is capable of curing MF patients is not available. Clinical trials with small molecule JAK1/2 inhibitors have proven beneficial in reducing the degree of splenomegaly and suppressing constitutional symptoms in a large fraction of patients with MF, but treatment with these agents do not extensively affect the degree of marrow fibrosis or eliminate molecular or cytogenetic abnormalities 8, 9 .
The only therapeutic option that can reverse the marrow fibrosis in MF patients 10,11 is an AHSCT. Initially AHSCT with myeloablative conditioning regimens was shown to be curative, especially in younger patients, thanks to a graft-versus-tumor effect from donor lymphocytes [12] [13] [14] [15] . Nevertheless, because of a very high transplant-related mortality in patients 45 years of age and older 16 , this approach was not routinely offered to the majority of MF patients. Studies from the MPD-RC and others [17] [18] [19] then demonstrated that reduced intensity conditioning regimens allow older patients to undergo AHSCT with limited treatment related mortality (TRM) and with a significant chance for long term survival. However, only a single multi-center large prospective study 20 of RIC AHSCT has been reported to date. In this study, patients were transplanted from related or unrelated donors after receiving a conditioning regimen including fludarabine, busulfan and rabbit anti-thymocyte globulin (ATG). The adverse prognostic factors that were Based on the initial transplant experience using a standard RIC regimen with fludarabine and melphalan, the MPD-RC launched in 2007 a prospective study of RIC-AHSCT using this regimen and investigated the efficacy of FluMel based RIC regimens in two parallel cohorts for matched sibling or matched unrelated donors transplantation, where ATG was utilized only in the latter group.
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PATIENTS AND METHODS

Patients
The MPD-RC 101 is a multicenter Phase 2 prospective study of reduced intensity AHSCT that was performed at 11 centers affiliated with the MPD-RC (6 from the US, 4 from Europe and 1 from Canada). Patients enrolled in the study had documented PMF or post-ET-or post-PV MF (blasts < 20%), age 18-65, no significant co-morbidities, intermediate or high risk Lille score, or low risk Lille score with a platelet count < 100 x 10 9 /L, a sibling or unrelated available stem cell donor, and a signed consent form according to the MPD-RC 101 protocol approved by each MPD-RC institution's Institutional Review Board (IRB) or equivalent Ethical Committee (for European centers).
The study included two parallel protocols: one for patients who received an AHSCT from a sibling donor and one who received grafts from unrelated donors. The study was conducted in accordance with the Declaration of Helsinki.
Donors
HLA matching was determined by low resolution molecular typing for sibling donors and by high-resolution molecular typing for both class I (A, B and C) and class II (HLA-DRB1
and HLA-DQB1) antigens for unrelated donors. Donor graft consisted of either unmanipulated bone marrow or peripheral blood hematopoietic stem cells (PBSC). The PBSC donors were mobilized with recombinant human granulocyte colony-stimulating factor (rhG-CSF) 10 μ g/kg s.c / day x 5 days and underwent PBSC collection by leukapheresis.
Treatment Plan
Patients were conditioned with the fludarabine 30 mg/m2/day intravenous (i.v.) for 5 days (day -6 to day -2) and melphalan 70 mg/m2/day i.v. for 2 days (day -2 to day -1).
Graft versus-host disease (GVHD) prophylaxis consisted of tacrolimus 0.03 mg/kg i.v. from d-2, methotrexate 10 mg/m 2 iv d+1 and 8 mg/m 2 d+3 and d+6. Thymoglobulin (rabbit antithymocyte globulin, Genzyme Corp. Cambridge, MA) at 4.5 mg/kg total dose was used as additional GVHD prophylaxis only in patients receiving a graft from an unrelated donor. 
Criteria for engraftment, response and GVHD
Study Design
The trial was designed to estimate progression free survival and overall survival of patients with MF undergoing an AHSCT prepared with a reduced intensity conditioning regimen in each of two cohorts separately (sibling and unrelated donor 
RESULTS
Patient Characteristics
The characteristics of patients in the sibling (n=32) and unrelated (n=34) groups are shown in Table 1 . Although the study was not designed to compare these two groups, the clinical characteristics of patients were similar. Of 66 patients, 63 were had intermediate or high risk MF according to the Lille score system, whereas 3 patients in the sibling group had low risk disease with thrombocytopenia. The median age at the time of transplant was 55 years in the sibling and 56 in the unrelated group, respectively. 
Engraftment
Donor cell engraftment was analyzed in each of the two groups separately ( Table 2 ). In the sibling group, neutrophil and platelet engraftment was achieved in 31/32 (97%) and 28/32 (88%) of patients, respectively. The median time to engraftment for neutrophils was 22 days (range: 0-62) and for platelets was 28 days (range:0-62). In the Unrel group, neutrophil and platelet engraftment occurred in 26/34 (76%) and 20/34 (59%).
Two patients in this group died prior to day 30 without hematopoietic cell engraftment.
The median time to engraftment for neutrophils was 18 days (range: 11-43) and for platelets was 28 days (range: 9-365).
An 
GVHD
Overall, 61% of the patients participating in the study did not experience greater than grade I acute GVHD. In the sibling group, 12/32 patients (38%) experienced aGVHD grade II-IV with 4 cases (12%) at grade III-IV. In the unrelated group, 14/34 patients (41%) had aGVHD grade II-IV, with 7 cases (21%) at grade III-IV ( Table 2 ). The degree of chronic GVHD could be assessed in 43 patients (28 sibling and 15 unrelated group, respectively). Of patients in the sibling cohort, 36% experienced cGVHD (extensive in 25%), while in the unrelated cohort 33% of the patients had cGVHD and in 20% it was extensive.
Mortality
The overall median follow-up for patients alive at last follow-up was 25 months (range: 10-73). In the sibling group 24/32 patients (75%) were alive. Progression of disease caused the death of 1 patient in this group while causes of non-relapse-mortality (NRM) in the remaining 7 patients (22%) included: secondary malignancy (n=1); aGVHD (n=3); hemorrhage (n=1); respiratory failure; (n=1); heart failure (n=1). In the unrelated group 11/34 patients (32%) are alive. Among the causes of death, 3 were related to progression of disease (in 2 cases after a second transplant) (9%), while 20 (59%) were due to transplant-related complications: aGVHD (n=5); hemorrhage (n=3); renal failure (n=2); pneumonia/respiratory failure (n= 2); venous occlusive disease (n=1); viral infection (n=1); other events secondary to graft failure (n=6).
Clinical Response
Clinical responses were assessed according to the IWG-MRT 2006 criteria in 46 patients (29 sibling and 17 unrelated transplants, respectively) who survived at least 180 days (Table 2 ). In the sibling group, the overall response rate (ORR) was 93% with 7 patients (25%) achieving a clinical CR, 8 patients a PR (29%), and 11 patients (39%) a CI. Two patients had stable disease and 1 patient had an unknown response. In the unrelated group, the ORR was 69% with 6/17 (35%) CR, 1 PR (6%) and 5 CI (29%). One patient experienced progression of the disease 180 days post-transplant. These results show that the clinical result of AHSCT from sibling or unrelated donors may be comparable for patients who achieve a sustained stem cell engraftment.
Survival
The median overall survival (OS) for the sibling group has not been reached while for the unrelated group was 6 months (95% CI: 3,25). A significantly higher risk of death was observed for patients receiving a transplant from an unrelated as compared to a sibling donor (Hazard Ratio 3.9, 95% CI: 1.8,8.9) (p<0.001). (Figure 1-top and 34 with an unrelated donor (74% HLA matched). As compared with the EBMT study, the present study included a lower number of patients with low risk Lille score (4.5 vs 16.5%). Moreover, low risk patients in our study had more advanced disease according to a modified Lille score 37 based on each of them being thrombocytopenic. Our conditioning regimen included melphalan instead of busulfan and ATG was administered only to recipients of the group receiving unrelated grafts. The present results in the sibling group showed 75% OS and are consistent with the EBMT study, as well with our prior retrospective study 17 of transplants from matched siblings. However, in transplants from unrelated donors the OS in the present study was 32%, significantly inferior to the sibling group (HR 3.9, 95% CI: 1.8,8.9) (p<0.001). As opposed to the EBMT trial, in our study we did not detect a difference between HLA matched and mismatched unrelated transplants. Since the relapse-related mortality was only 6% in the study (3% in the sibling and 9% in the unrelated group), the high rate of NRM in the unrelated group was frequently secondary to graft failure. Previous studies have reported controversial conclusions concerning the risk associated with utilizing an unrelated donor. Similar to the EBMT prospective trial, a retrospective study from Seattle 37 did not find a significant For personal use only. on June 9, 2017. by guest www.bloodjournal.org From transplants was 34% and that using an unrelated donor was an independent adverse prognostic factor 39 . Given that in our study we did not observe any difference in the outcome of PMF and post-ET-or post-PV-MF, our findings seem consistent with the EBMT retrospective report. Prior retrospective data from the Italian (GITMO) 36 and
French (SFGM-TC) 35 registries also showed significantly higher rates of NRM in transplants from non-sibling donors. An intial analysis 39 from the Center for International
Blood and Marrow Transplant Registry (CIBMTR) including MF patients receiving mostly a myeloablative regimen found a 55% and 70% overall mortality in sibling and unrelated transplants, respectively. A more recent retrospective study 41 from the CIBMTR of 233 patients with MF who received a RIC transplant showed a better outcome for those who received a transplant from a matched sibling as opposed to a matched unrelated donor.
In another study of RIC HSCT, Bacigalupo et al 42 reported that the three independent adverse prognostic factors for outcome of AHSCT transplant for myelofibrosis were: any type of donor other than a matched sibling, a large spleen, and an excessive number of red blood cell transfusions prior to transplant. This scoring system suggests that other factors related to the disease can affect the transplant outcome and will be validated in future prospective trials. However, consistent with this study we found that transplant from an Unrel donor carried a higher risk of death.
None of the studies of transplant in MF have evaluated the possible role of HLA antibodies, especially in the Unrel setting, as a possible factor correlating with graft failure. Unfortunately these data were not measured in our study and we cannot rule out that this may have influenced the excessive rate of rejection in our cohort of unrelated transplants. Based on risk factors identified in prior studies, we analyzed whether the limited survival in unrelated transplants were related to HLA mismatch, age>57 or It is possible that differences between the only two prospective cooperative studies, ours and the EBMT one, may be due primarily to the different conditioning regimen. However, other possible differences could include a lower number of low risk patients in our study or the different type of ATG utilized. Since FluMel regimen was associated with low rates of graft failure, relapse and NRM in sibling transplants, we assume that the different results obtained in the unrelated group may be due, in part, to a strong in-vivo immunomodulatory effect/ in vivo T cell depletion of the graft due to the combination of FluMel/ATG as a conditioning regimen that could have favored a host-anti-donor immune response. The immune effect of the conditioning may play an important role in the success that will be encountered with new protocols that are being designed to include ruxolitinib or other JAK 1/2 inhibitors (MPD-RC114) [43] [44] [45] [46] . In fact, these agents are being investigated in AHSCT because they can rapidly reduce constitutional symptoms and the spleen size thanks to a marked suppression of proinflammatory cytokines 9 , but also for a possible immunosuppressive activity that may limit GVHD 47 . Because of these considerations, and the high rate of graft failure in unrelated transplants prepared with FluMelATG observed in this study, the MPD-RC has recently launched a new prospective study combining ruxolitinib with a FluBuATG RIC regimen.
Based on the results of two large prospective studies of RIC AHSCT in MF, regimens including melphalan or busulfan are both very effective in transplants from sibling donors. However, a busulfan-based regimen seems preferable in case of transplant from an unrelated donor since comparable results in sibling or unrelated transplants were observed in the EBMT study using a reduced intensity regimen and previously in a large retrospective study using a myeloablative regimen 37 . These studies also suggest that an initial search for matched donors should be performed for all the MF patients at For
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